ALNY
Alnylam Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
239.00
▲ 9.70 (4.23%)
MARKET · —
Price
Open
229.30
Prev close
229.30
Day high
238.97
Day low
228.34
Volume
1.87M
Market cap
—
P/E (TTM)
—
52W range
197.81 – 495.55
Trailing performance
Returnvs SPY
1W
+3.31%
+4.7%
1M
-12.10%
-15.8%
3M
-21.39%
-24.5%
6M
-29.74%
-40.8%
YTD
-40.60%
-52.9%
1Y
-48.46%
-68.5%
3Y
+29.49%
-44.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
227.92
+4.86% from price
SMA 20
232.35
+1.66% from price
SMA 50
266.65
-11.41% from price
SMA 100
286.13
-16.47% from price
SMA 200
331.03
-28.64% from price
EMA 12
231.77
+3.12% from price
EMA 26
242.18
-1.31% from price
EMA 50
258.72
-7.62% from price
RSI (14)
46.7
Neutral
MACD (12,26,9)
-10.41
Hist 3.55
ATR (14)
9.84
4.17% of price
Realised vol 30D
107.0%
Annualised
Bollinger upper
279.47
20, 2σ
Bollinger lower
185.24
20, 2σ
50 / 200 cross
Death
266.65 vs 331.03
Trend bias
Below 200
-28.64%
Risk profile
Beta vs SPY
0.35
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
107.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-58.2%
Peak to trough
Max drawdown 5Y
-58.2%
Peak to trough
ATR 14
9.84
4.17% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Moderna's Melanoma Result Landed On A Market Positioned The Other Way
Trefis · 2d ago
Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis
Business Wire · 4d ago
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Motley Fool · 6d ago
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
TipRanks · 11d ago
Drugs that missed the mark in pharma’s last earnings round
Pharma Voice · 11d ago
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Zacks · 16d ago
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 17d ago
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
Motley Fool · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.